- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03602118
Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures
A Randomized, Double-blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, parallel-group, Phase 3 study to evaluate the efficacy of the administration of Phenobarbital Sodium Injection, USP in participants who have suffered from a clinical seizure. As neonatal seizures can have long-term adverse effects, including death, placebo-controlled studies are not appropriate for this population. This study is designed to show phenobarbital is effective at preventing subsequent seizures by demonstrating greater efficacy at the higher (40 mg/kg) dose compared to the lower dose (20 mg/kg). It is important to note that, although phenobarbital is not approved for the treatment of neonatal seizures, it is commonly used for this indication and is considered the first-line therapy in the United States, (US), and by the World Health Organization. The minimum recommended dose of phenobarbital used to treat neonatal seizures is 20 mg/kg. Therefore, the lower dose of phenobarbital used in this study is considered an "effective" dose for the treatment of neonatal seizures. The design of this study allows for assessment of the minimum recommended dose with the maximum recommended dose to show the increased efficacy of the high dose in various measures of reduction in seizures.
Study participants undergoing electrographic or electroclinical seizures lasting 10 seconds or longer will be randomized in a 1:1 fashion between the 2 treatment arms. Participants will receive either a 20-mg/kg or 40-mg/kg loading dose of Phenobarbital Sodium Injection, USP upon confirmation that the seizure was not due to metabolic imbalances. Randomization of participants with hypoxic-ischemic encephalopathy, (HIE), will be stratified between the dosing groups. Participants will further be stratified by treatment group for pharmacokinetics, (PK), analysis timepoints due to the limitations on the number of pharmacokinetics, (PK), samples that can be taken from each patient. After cessation of seizures the participants will remain in the hospital for 24 hours for continuous monitoring by electroencephalogram, (EEG).
According to recommended dosing of phenobarbital, participants in the 20-mg/kg treatment arm in whom seizure activity does not resolve after the first dose (20 mg/kg) will be given phenobarbital in 10-mg/kg increments (each hour) until the seizure activity resolves, up to a maximum total dose of 40 mg/kg. If the seizure activity is still not resolved, participants will be given a second-line anticonvulsant. The second-line therapy given will be determined by the attending physician and recorded in the study documentation. Participants in the 40-mg/kg treatment arm in whom seizure activity does not resolve after the initial loading dose of phenobarbital will be given a second-line anticonvulsant. The second therapy given will be determined by the attending physician and recorded in the study documentation.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Parental informed consent
- Infants born at ≥ 35 + 0/7 weeks gestational age AND age 0-28 days after birth
- Has evidence of an electrographic seizure lasting at least 10 seconds
- Undergoing continuous electroencephalogram, (EEG), monitoring, including infants with hypoxic-ischemic encephalopathy concurrently treated with hypothermic cooling
Exclusion Criteria:
- If the seizures are solely due to a transient abnormality, easily correctable, and unlikely to recur (for example, transient electrolyte abnormalities)
- If the infant has been diagnosed with or there is a strong suspicion of an inborn error of metabolism, significant brain malformation, or microcephaly (< 3rd percentile)
- If the infant has been diagnosed with an intrauterine viral infection
- If the infant is not expected to survive to discharge
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Phenobarbital Sodium Injection 20 mg
Once participants are deemed to be eligible for participation in the study and randomized to the lower dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
|
Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
Other Names:
|
Active Comparator: Phenobarbital Sodium Injection 40 mg
Once participants are deemed to be eligible for participation in the study and randomized to the higher dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
ministered intravenously over the course of 30 minutes.
|
Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A change in the number of seizures in neonatal infants after administration of phenobarbital sodium injection
Time Frame: The 24 hour period after the initial loading dose of pheonobarbital sodium injection is given.
|
Once a neonate has been identified as having a seizure by electroencephalogram he/she will be randomized to one of two doses of phenobarbital sodium injection, (20 mg/kg or 40 mg/kg).
The number of neonates in each group will be observed for the end of any further seizures, also verified by electroencephalogram.
In addition to observing when all seizure activity ended after the initial loading dose, the number of infants requiring a second dose of phenobarbital or second-line anti-convulsant therapy to treat unresolved or subsequent seizures will be observed in each randomization group, (phenobarbital sodium injection 20mg/kg or 40mg/kg) following the initial loading dose.
|
The 24 hour period after the initial loading dose of pheonobarbital sodium injection is given.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Seizures
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Hypnotics and Sedatives
- GABA Modulators
- GABA Agents
- Anticonvulsants
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Phenobarbital
Other Study ID Numbers
- 1021.121.039.00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Seizure
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Active, not recruitingEpilepsy | Neonatal SeizureItaly
-
Cambridge University Hospitals NHS Foundation TrustNot yet recruiting
-
Children's Hospital of Fudan UniversityChengdu Women's and Children's Central Hospital; Xiamen Children's Hospital; Kunming...WithdrawnNeonatal SeizureChina
-
Yonsei UniversityCompleted
-
Children's Hospital of Fudan UniversityChengdu Women's and Children's Central Hospital; Xiamen Children's Hospital; Kunming... and other collaboratorsRecruiting
-
Balikesir UniversityCompleted
-
Assiut UniversityNot yet recruitingNeonatal Seizure
-
University of California, San DiegoUniversity of Minnesota; Rady Children's Hospital, San Diego; Middlemore Hospital... and other collaboratorsRecruitingHypoxic-Ischemic Encephalopathy | Neonatal Encephalopathy | Neonatal Seizure | Seizure NewbornUnited States, New Zealand
-
Children's Hospital of Fudan UniversityRecruitingSeizures | Seizure Disorder | Epileptic Encephalopathy | Seizures, Generalized | Seizure Newborn | Epileptic Encephalopathy, Neonatal-onset | Epileptic Encephalopathy, Infant-onset | KCNQ2China
-
University of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsActive, not recruitingEpilepsy | Inflammatory Response | Seizures | Neonatal SeizureUnited States
Clinical Trials on Phenobarbital Sodium Injection
-
University of North Carolina, Chapel HillRecruitingStroke | Brain Ischemia | Brain Injuries, Traumatic | Heart Arrest | Intracranial Hemorrhages | Brain Hypoxia | Coma | Hypoxia-Ischemia, Brain | Persistent Vegetative State | Brain Injuries, AcuteUnited States
-
University of California, San DiegoUniversity of Minnesota; Rady Children's Hospital, San Diego; Middlemore Hospital... and other collaboratorsRecruitingHypoxic-Ischemic Encephalopathy | Neonatal Encephalopathy | Neonatal Seizure | Seizure NewbornUnited States, New Zealand
-
NEMA Research, Inc.TerminatedEpilepsy, Benign NeonatalUnited States, Jordan
-
Tongji HospitalRecruiting
-
Beijing Tiantan HospitalNot yet recruitingEdema Brain
-
National Institute of Neurological Disorders and...Completed
-
Livzon Pharmaceutical Group Inc.UnknownCarcinogenic FatigueChina
-
The Second Hospital of Hebei Medical UniversityUnknownCerebral Infarction | Cerebral EdemaChina
-
Southeast University, ChinaUnknown
-
PfizerCompletedMacular Edema | Retinal Disease | Diabetic MellitusJapan